WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) reported a third-quarter net loss of $20.5 million, up from $11.9 million a year earlier, as increased research spending supported…
WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) reported a third-quarter net loss of $20.5 million, up from $11.9 million a year earlier, as increased research spending supported the global …
Source disclosure
This is a source-linked briefing. Read the original report from Mychesco .